• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

测定患有胰腺肿瘤患者的金属蛋白酶及其抑制剂的血液水平。

The estimation of metaloproteinases and their inhibitors blood levels in patients with pancreatic tumors.

机构信息

Department of Thoracic, General and Oncological Surgery, Medical University, 113 Zeromskiego Street, 90-549 Lodz, Poland.

出版信息

World J Surg Oncol. 2013 Jun 14;11:137. doi: 10.1186/1477-7819-11-137.

DOI:10.1186/1477-7819-11-137
PMID:23768069
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3701564/
Abstract

BACKGROUND

The aim of the study was to evaluate the concentration of proteolytic enzymes, MMP-2 and MMP-9, and their tissue inhibitors, TIMP-1 and TIMP-2, in the blood of patients with benign and malignant pancreatic tumors.

METHODS

MMP-2, MMP-9, TIMP-1, and TIMP-2 were evaluated in the patients with benign and malignant pancreatic tumors before surgery and in the 30-day follow-up. The study covered 134 patients aged 54 to 76 years, who were divided into groups by TNM staging.

RESULTS

Before the operation, the highest mean concentration of MMP-2 was found in patients with unresectable cancer, whereas the highest level of MMP-9 was in patients with resectable cancer. The highest level of TIMP-1 was noted in patients with inflammatory tumors. In 1 month following the operation, the highest level of MMP-2 was also in patients with unresectable cancer and the highest level of TIMP-2 in patients with inflammatory tumors.

CONCLUSIONS

The evaluation of the level of the studied cytokines in the pancreatic tumor patients can be diagnostically significant in the differentiation of benign and malignant changes. The changes in the levels of the studied enzymes and their inhibitors can have a prognostic value in the clinical severity of pancreatic cancer.

摘要

背景

本研究旨在评估蛋白酶 MMP-2 和 MMP-9 及其组织抑制剂 TIMP-1 和 TIMP-2 在良性和恶性胰腺肿瘤患者血液中的浓度。

方法

在手术前和 30 天随访中评估了患有良性和恶性胰腺肿瘤的患者的 MMP-2、MMP-9、TIMP-1 和 TIMP-2。该研究涵盖了 134 名年龄在 54 至 76 岁之间的患者，他们根据 TNM 分期分为不同组。

结果

在手术前，不可切除癌症患者的 MMP-2 平均浓度最高，而可切除癌症患者的 MMP-9 水平最高。炎症性肿瘤患者的 TIMP-1 水平最高。手术后 1 个月，不可切除癌症患者的 MMP-2 水平最高，炎症性肿瘤患者的 TIMP-2 水平最高。

结论

评估胰腺肿瘤患者研究细胞因子的水平可以在良性和恶性变化的鉴别诊断中具有诊断意义。研究酶及其抑制剂水平的变化在胰腺癌的临床严重程度上可能具有预后价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e256/3701564/45e099a2345f/1477-7819-11-137-6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e256/3701564/d79ce1289d31/1477-7819-11-137-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e256/3701564/182591670f1b/1477-7819-11-137-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e256/3701564/9acfc57b0104/1477-7819-11-137-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e256/3701564/bf09cd1620d0/1477-7819-11-137-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e256/3701564/cdd5f741e49b/1477-7819-11-137-5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e256/3701564/45e099a2345f/1477-7819-11-137-6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e256/3701564/d79ce1289d31/1477-7819-11-137-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e256/3701564/182591670f1b/1477-7819-11-137-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e256/3701564/9acfc57b0104/1477-7819-11-137-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e256/3701564/bf09cd1620d0/1477-7819-11-137-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e256/3701564/cdd5f741e49b/1477-7819-11-137-5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e256/3701564/45e099a2345f/1477-7819-11-137-6.jpg

相似文献

1
The estimation of metaloproteinases and their inhibitors blood levels in patients with pancreatic tumors.测定患有胰腺肿瘤患者的金属蛋白酶及其抑制剂的血液水平。
World J Surg Oncol. 2013 Jun 14;11:137. doi: 10.1186/1477-7819-11-137.
2
Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.肺癌中血清基质金属蛋白酶-2、-9及金属蛋白酶组织抑制剂-1、-2——TIMP-1作为一种预后标志物
Anticancer Res. 2000 Mar-Apr;20(2B):1311-6.
3
Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.基质金属蛋白酶-2（MMP-2）和-9（MMP-9）及其组织抑制剂（TIMP-1和TIMP-2）在低恶性潜能（LMP）卵巢肿瘤与恶性卵巢肿瘤鉴别诊断中的作用
Anticancer Res. 2007 Jul-Aug;27(4C):2753-8.
4
Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.卵巢肿瘤中的明胶酶及其组织抑制剂；TIMP-1是一个预测性及预后性因素。
Gynecol Oncol. 2005 Dec;99(3):656-63. doi: 10.1016/j.ygyno.2005.07.009. Epub 2005 Aug 19.
5
Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.术前血清基质金属蛋白酶（MMP - 2、MMP - 9）及基质金属蛋白酶组织抑制剂（TIMP - 1、TIMP - 2）分析在结直肠癌中的价值有限。
Anticancer Res. 2000 Mar-Apr;20(2B):1085-91.
6
The Behavior of MMP-2, MMP-7, MMP-9, and Their Inhibitors TIMP-1 and TIMP-2 in Adenoma-Colorectal Cancer Sequence.MMP-2、MMP-7、MMP-9 及其抑制剂 TIMP-1 和 TIMP-2 在腺瘤-结直肠癌序列中的行为。
Dig Dis. 2021;39(3):217-224. doi: 10.1159/000511765. Epub 2020 Sep 22.
7
The matrix metalloproteinase-7 and pro-enzyme of metalloproteinase-1 as a potential marker for patients with rectal cancer without distant metastasis.基质金属蛋白酶-7和金属蛋白酶-1原酶作为无远处转移直肠癌患者的潜在标志物。
Tumour Biol. 2015 May;36(5):3629-35. doi: 10.1007/s13277-014-3000-z. Epub 2014 Dec 31.
8
Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer.血管细胞黏附分子（VCAM）和基质金属蛋白酶-2（MMP-2）的循环水平可能有助于识别侵袭性更强的前列腺癌患者。
Curr Cancer Drug Targets. 2008 May;8(3):199-206. doi: 10.2174/156800908784293613.
9
Clinical Significance of Matrix Metalloproteinases in Blood Plasma of Patients with Gastric Cancer.基质金属蛋白酶在胃癌患者血浆中的临床意义
Bull Exp Biol Med. 2019 Jan;166(3):373-376. doi: 10.1007/s10517-019-04353-y. Epub 2019 Jan 9.
10
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia.混合型血脂异常中金属蛋白酶2和9水平及其抑制剂的评估
Clin Invest Med. 2009 Apr 1;32(2):E124-32. doi: 10.25011/cim.v32i2.6030.

引用本文的文献

1
Anticancer Activity of Melittin-Containing Bee Venom Fraction Against Glioblastoma Cells In Vitro.含蜂毒肽的蜂毒组分对胶质母细胞瘤细胞的体外抗癌活性
Int J Mol Sci. 2025 Mar 7;26(6):2376. doi: 10.3390/ijms26062376.
2
α-Solanine Inhibits Proliferation, Invasion, and Migration, and Induces Apoptosis in Human Choriocarcinoma JEG-3 Cells In Vitro and In Vivo.α-茄碱抑制人绒毛膜癌 JEG-3 细胞的增殖、侵袭和迁移，并诱导其体外和体内凋亡。
Toxins (Basel). 2021 Mar 13;13(3):210. doi: 10.3390/toxins13030210.
3
Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression?

本文引用的文献

1
Vascular proliferation is increased in basal-like breast cancer.基底样乳腺癌中血管增生增加。
Breast Cancer Res Treat. 2011 Dec;130(3):1063-71. doi: 10.1007/s10549-011-1740-7. Epub 2011 Aug 28.
2
Claudin-18 is an early-stage marker of pancreatic carcinogenesis.Claudin-18 是胰腺癌变的早期标志物。
J Histochem Cytochem. 2011 Oct;59(10):942-52. doi: 10.1369/0022155411420569. Epub 2011 Aug 10.
3
Angiogenin as a molecular target for the treatment of prostate cancer.血管生成素作为前列腺癌治疗的分子靶点。
胰腺导管腺癌中的基质金属蛋白酶：疾病进展的关键驱动因素？
Biology (Basel). 2020 Apr 18;9(4):80. doi: 10.3390/biology9040080.
4
Matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor 2 (TIMP-2) in pancreatic cancer (PC).胰腺癌（PC）中的基质金属蛋白酶2（MMP - 2）及其组织抑制剂2（TIMP - 2）
Oncotarget. 2019 Jan 8;10(3):395-403. doi: 10.18632/oncotarget.26571.
5
Prognostic significance of plasma matrix metalloprotease-2 in pancreatic cancer patients.血浆基质金属蛋白酶-2 在胰腺癌患者中的预后意义。
Indian J Med Res. 2017 Sep;146(3):334-340. doi: 10.4103/ijmr.IJMR_1348_15.
6
Antitumor efficacy of α-solanine against pancreatic cancer in vitro and in vivo.α-茄碱对胰腺癌的体内外抗肿瘤活性。
PLoS One. 2014 Feb 5;9(2):e87868. doi: 10.1371/journal.pone.0087868. eCollection 2014.
Curr Cancer Ther Rev. 2011 May;7(2):83-90. doi: 10.2174/1573394711107020083.
4
Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.用于胰腺导管腺癌预后的组织生物标志物：系统评价和荟萃分析。
Clin Cancer Res. 2011 May 15;17(10):3316-31. doi: 10.1158/1078-0432.CCR-10-3284. Epub 2011 Mar 28.
5
Serum MMP 2 and TIMP 2 in patients with inguinal hernias.血清基质金属蛋白酶 2 和基质金属蛋白酶组织抑制剂 2 在腹股沟疝患者中的变化。
Eur J Clin Invest. 2011 Jun;41(6):584-8. doi: 10.1111/j.1365-2362.2010.02445.x. Epub 2011 Feb 8.
6
Angiogenesis in superficial esophageal squamous cell carcinoma: magnifying endoscopic observation and molecular analysis.浅表性食管鳞癌中的血管生成：放大内镜观察与分子分析。
Dig Endosc. 2010 Oct;22(4):259-67. doi: 10.1111/j.1443-1661.2010.01010.x. Epub 2010 Aug 12.
7
Plectin-1 as a novel biomarker for pancreatic cancer.Plectin-1 作为一种新型胰腺癌生物标志物。
Clin Cancer Res. 2011 Jan 15;17(2):302-9. doi: 10.1158/1078-0432.CCR-10-0999. Epub 2010 Nov 23.
8
[Survival, mortality and quality of life after pylorus-preserving or classical Whipple operation. A systematic review with meta-analysis].[保留幽门或经典胰十二指肠切除术后的生存、死亡率及生活质量。一项系统评价与荟萃分析]
Chirurg. 2010 May;81(5):454-71. doi: 10.1007/s00104-009-1829-2.
9
Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor.胰腺癌患者血清基质金属蛋白酶-9及其抑制剂（金属蛋白酶组织抑制剂-1）检测的临床意义：基质金属蛋白酶-9作为独立预后因素
Pancreas. 2009 Aug;38(6):613-8. doi: 10.1097/MPA.0b013e3181a488a0.
10
Degradation of collagen by metalloproteinase 2 in patients with abdominal hernias.金属蛋白酶2对腹疝患者胶原蛋白的降解作用
Eur Surg Res. 2009;42(2):118-21. doi: 10.1159/000187643. Epub 2008 Dec 22.